CLAIMS

1. Use of method of a monoclonal antibody or an antigen binding fragment or peptide thereof which specifically binds epidermal growth factor receptor (EGF-R), wherein the antibody is a chimeric or a humanized monoclonal antibody which contains the following complementarity determining regions (CDRs):
   CDR1 of the light chain: RSSQNIVHSNGNTYLD (SEQ ID NO: 1),
   CDR2 of the light chain: KVSNRFS (SEQ ID NO: 2),
   CDR3 of the light chain: FQYSHVPWT (SEQ ID NO: 3),
   CDR1 of the heavy chain: NYYIY (SEQ ID NO: 4),
   CDR2 of the heavy chain: GINPTSGGSNFNEKFKT (SEQ ID NO: 5),
   CDR3 of the heavy chain: QGLWFDSDGRGFDF (SEQ ID NO: 6)
   in the manufacture of a medicament for treating a population of patients having been diagnosed with pancreatic ductal adenocarcinoma (PDAC), wherein the pancreatic ductal adenocarcinoma expresses the wild-type protein of at least one member of the RAS gene family selected from the KRAS wild-type, the HRAS wild-type or the NRAS wild-type.